埃克替尼治疗老年晚期表皮生长因子受体基因突变非小细胞肺癌患者的临床疗效 - Suppr | 超能文献

[Clinical effect of icotinib in treatment of elderly advanced non-small cell lung cancer patients with EGFR mutations].

作者信息

Ren Y L, Sheng J, Zhou X Y, Fang Y, Pan H M

机构信息

Department of Oncology, Shao Yifu Hospital Affiliated to Zhejiang University, Hangzhou 310016, China.

出版信息

Zhonghua Zhong Liu Za Zhi. 2019 Feb 23;41(2):152-153. doi: 10.3760/cma.j.issn.0253-3766.2019.02.014.

DOI:10.3760/cma.j.issn.0253-3766.2019.02.014

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

[Clinical effect of icotinib in treatment of elderly advanced non-small cell lung cancer patients with EGFR mutations].埃克替尼治疗老年晚期表皮生长因子受体基因突变非小细胞肺癌患者的临床疗效

Zhonghua Zhong Liu Za Zhi. 2019 Feb 23;41(2):152-153. doi: 10.3760/cma.j.issn.0253-3766.2019.02.014.

2

[Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified].[已确定埃克替尼对具有表皮生长因子受体（EGFR）状态的晚期非小细胞肺癌患者的疗效]

Zhongguo Fei Ai Za Zhi. 2013 Mar;16(3):138-43. doi: 10.3779/j.issn.1009-3419.2013.03.04.

3

Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi-center study.晚期非小细胞肺癌伴罕见突变表皮生长因子受体患者对伊可替尼原发性耐药的潜在机制：一项多中心研究。

Cancer Sci. 2020 Feb;111(2):679-686. doi: 10.1111/cas.14277. Epub 2020 Jan 16.

4

Clinicopathologic characteristics and outcome of patients with different EGFR mutations.不同表皮生长因子受体（EGFR）突变患者的临床病理特征及预后

Asia Pac J Clin Oncol. 2019 Jun;15(3):166-171. doi: 10.1111/ajco.13072. Epub 2018 Oct 11.

5

Icotinib alone or with bevacizumab as first-line therapy in Chinese patients with advanced nonsquamous non-small cell lung cancer and activating EGFR mutations: A retrospective study.厄洛替尼单药或联合贝伐珠单抗一线治疗表皮生长因子受体突变阳性的晚期非鳞状非小细胞肺癌中国患者的回顾性研究。

Thorac Cancer. 2021 Sep;12(17):2369-2374. doi: 10.1111/1759-7714.14079. Epub 2021 Jul 13.

6

Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes.埃克替尼对不同表皮生长因子受体（EGFR）表型的晚期非小细胞肺癌的影响。

Cell Biochem Biophys. 2014 Sep;70(1):553-8. doi: 10.1007/s12013-014-9955-y.

7

Icotinib plus osimertinib overcome epidermal growth factor receptor 19del/T790 M/C797S/V834L quadruplet resistance mutation in a patient with non-small cell lung cancer.埃克替尼联合奥希替尼克服了一名非小细胞肺癌患者的表皮生长因子受体19del/T790M/C797S/V834L四重耐药突变。

Chin Med J (Engl). 2019 May 5;132(9):1115-1116. doi: 10.1097/CM9.0000000000000196.

8

A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).一项关于埃克替尼治疗晚期非小细胞肺癌（NSCLC）的单臂、多中心、安全性监测的IV期研究。

Lung Cancer. 2014 Nov;86(2):207-12. doi: 10.1016/j.lungcan.2014.08.014. Epub 2014 Sep 16.

9

[China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2015 version)].《中国埃克替尼治疗非小细胞肺癌专家共识（2015年版）》

Zhongguo Fei Ai Za Zhi. 2015 Jul;18(7):397-400. doi: 10.3779/j.issn.1009-3419.2015.07.01.

10

Icotinib: efficacy in different solid tumors and gene mutations.厄洛替尼：不同实体瘤及基因突变患者中的疗效。

Anticancer Drugs. 2020 Mar;31(3):205-210. doi: 10.1097/CAD.0000000000000861.

引用本文的文献

1

[Consensus of Chinese Experts on Medical Treatment of Advanced Lung Cancer  in the Elderly (2022 Edition)].《中国老年晚期肺癌诊疗专家共识（2022年版）》

Zhongguo Fei Ai Za Zhi. 2022 Jun 20;25(6):363-384. doi: 10.3779/j.issn.1009-3419.2022.101.25.